New study reveals link between aspirin use, Type 2 diabetes
NEW YORK The results of a study published in the American Journal of Medicine suggest there may be an association between aspirin use and a decreased risk of developing Type 2 diabetes.
To investigate, researchers from University Graduate School of Medicine, Kyoto, Japan, analyzed data from the Physician’s Health Study, which includes 22,071 seemingly healthy male participants, and has accumulated 22 years of follow-up data.
The participants provide self reports of history of diabetes, aspirin use and various lifestyle factors at study entry and in yearly follow-up questionnaires.
A total of 1,719 cases of diabetes were reported during follow-up. The men who reported taking any aspirin were 14% less likely to develop diabetes, compared with those who did not take aspirin.
Non-aspirin, non-steroidal anti-inflammatory drugs were not associated with a decreased risk of developing diabetes.
“Decreased risk of Type 2 diabetes may be added to the list of clinical benefits of aspirin,” researchers concluded. “Future studies are warranted to further investigate this association.”
Study finds that Mannatech supplement can improve vision, memory
COPPELL, Texas One tablespoon of a dietary supplement can improve mental functioning, a study indicates.
The study, by researchers at Howard University and published in the journal Perceptual & Motor Skills, indicated that a tablespoon of Mannatech’s supplement Ambrotose can “significantly improve” visual discrimination and working memory.
“The results of this study are impressive because they show significant improvement in the perceptual capabilities of healthy adults, which indicates that Ambrotose complex can benefit everyone,” researcher Atiya Stancil said.
Stancil and fellow researcher Leslie Hicks conducted the randomized, double-blind, placebo-controlled study on 62 healthy young adults.
WellSpring’s anti-nausea medication proves successful in market
SARASOTA, Fla, WellSpring Pharmaceutical on Tuesday announced that its anti-nausea liquid Emetrol is now the leading product in its category based on trailing 52-week sales ended Jan. 14, citing data from Information Resources Inc.
Over that 52-week period, Emetrol marketshare grew to 51.7% of the category based on sales growth of more than 24%.
WellSpring recently rolled out a national advertising campaign targeting women between the ages of 25 and 34, the company stated. And the National Association of Pediatric Nurse Practitioners recently selected Emetrol for editorial content in an upcoming issue.
“The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by pediatricians for children under their care, has proven to be one of the most important attributes of the brand,” stated WellSpring president and CEO Robert Vukovich.